XML 30 R19.htm IDEA: XBRL DOCUMENT
v3.25.2

GOODWILL AND OTHER INTANGIBLE ASSETS | 6 Months Ended
--- | ---
Jun. 30, 2025
Goodwill and Intangible Assets Disclosure [Abstract] |
GOODWILL AND OTHER INTANGIBLE ASSETS | GOODWILL AND OTHER INTANGIBLE ASSETS Goodwill The changes in the carrying amounts in Goodwill were as follows:
Dollars in millions |  |  |
Balance at December 31, 2024 | $ | 21,719 |  |  |
Currency translation and other adjustments | 57 |  |  |
Balance at June 30, 2025 | $ | 21,776 |  |  |
Other Intangible Assets Other intangible assets consisted of the following:
| Estimated Useful Lives |  | June 30, 2025 |  | December 31, 2024
Dollars in millions |  | Gross carrying amounts |  | Accumulated amortization |  | Other intangible assets, net |  | Gross carrying amounts |  | Accumulated amortization |  | Other intangible assets, net
R&D technology | 6 years |  | $ | 1,980 |  |  | $ | (440) |  |  | $ | 1,540 |  |  | $ | 1,980 |  |  | $ | (275) |  |  | $ | 1,705 |
Acquired marketed product rights | 3 – 17 years |  | 61,927 |  |  | (50,154) |  |  | 11,773 |  |  | 61,876 |  |  | (48,659) |  |  | 13,217 |
Capitalized software | 3 – 10 years |  | 1,554 |  |  | (1,174) |  |  | 380 |  |  | 1,499 |  |  | (1,099) |  |  | 400 |
IPRD |  |  | 7,685 |  |  | — |  |  | 7,685 |  |  | 7,985 |  |  | — |  |  | 7,985 |
Total |  |  | $ | 73,146 |  |  | $ | (51,768) |  |  | $ | 21,378 |  |  | $ | 73,340 |  |  | $ | (50,033) |  |  | $ | 23,307 |
Amortization expense of Other intangible assets was $864 million and $1.7 billion during the three and six months ended June 30, 2025 and $2.4 billion and $4.8 billion during the three and six months ended June 30, 2024, respectively. During the three months ended June 30, 2025, $300 million of IPRD impairment charges were recorded in Research and development expense for two oncology assets. The charges represented a partial write-down of each asset driven by revised cash flow projections and updated clinical development timelines. During the three months ended June 30, 2024, a $280 million impairment charge was recorded in Cost of products sold resulting from lower revised cash flow projections for Inrebic. The charge represented a partial impairment based on the excess of the asset’s carrying value over its estimated fair value using discounted cash flow projections. Additionally, a $590 million IPRD impairment charge for alnuctamab was recorded in Research and development expense in connection with portfolio prioritization. Alnuctamab was being studied as a potential treatment for hematologic diseases and was obtained in the acquisition of Celgene. The charge represented a full write-down of the asset.

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for goodwill and intangible assets. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-30/tableOfContent Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-20/tableOfContent + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration